MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities/(purchase) of short-term
investments, net of...
-$10,895,109
Cash from asset
disposition
$850
Net cash provided by
(used in) investing...
$10,895,959
Net increase
(decrease) in cash and cash...
$2,266,517
Canceled cashflow
$8,629,442
Accounts payable
$1,903,517
Stock-based compensation
expense
$1,496,989
Other current
liabilities
$1,209,367
Other current assets
-$617,231
Depreciation and
amortization
$172,886
Right-of-use assets
$170,367
Other assets
-$18,001
Loss from disposal of
assets
-$7,615
Net cash used in
operating activities
-$8,557,917
Net cash used in
financing activities
-$71,525
Canceled cashflow
$5,595,973
Net loss
-$12,509,361
Repayment of insurance
premium loan payable
$71,525
Accrued payroll
liabilities
-$1,035,082
Prepaid expenses
$396,781
Operating lease liability
-$212,666
Back
Back
Cash Flow
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)
source: myfinsight.com